Pfizer Inc (PFE): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Pfizer ( PFE) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.6%. By the end of trading, Pfizer rose 38 cents (1.4%) to $27.41 on light volume. Throughout the day, 24.2 million shares of Pfizer exchanged hands as compared to its average daily volume of 32.4 million shares. The stock ranged in a price between $26.92-$27.54 after having opened the day at $26.93 as compared to the previous trading day's close of $27.03. Other companies within the Drugs industry that increased today were: Zogenix ( ZGNX), up 40.5%, Optimer Pharmaceuticals ( OPTR), up 13.2%, Oncothyreon ( ONTY), up 9.7%, and Sarepta Therapeutics ( SRPT), up 8.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. Pfizer has a market cap of $197.61 billion and is part of the health care sector. The company has a P/E ratio of 21.3, above the S&P 500 P/E ratio of 17.7. Shares are up 7% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Pfizer a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, ProPhase Labs ( PRPH), down 20%, Novogen ( NVGN), down 11.4%, Prima Biomed ( PBMD), down 9.2%, and Repros Therapeutics ( RPRX), down 5.9%, were all laggards within the drugs industry with Keryx Biopharmaceuticals ( KERX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.